Obtenez une réponse de cet employeur
Votre CV et votre lettre de motivation, adaptés exactement à ce que l’employeur recherche.
OXB (Oxford Biomedica) in Oxford, UK is seeking a Senior Director, Corporate Counsel to join the Legal team on a 12-month fixed-term contract. You will provide corporate and company secretarial advice, partnering with the Chief Legal Officer to protect the Group and enable its strategy.
The role covers governance, capital markets, M&A, compliance, and regulatory matters, including FTSE listing support. Qualified solicitor in England & Wales with PQE in listed or regulated settings is required.
Location: Oxford, GB
Company: oxfordbiom
Join Us in Changing Lives
At OXB, our people are at the heart of everything we do. We’re on a mission to enable life-changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day:Responsible, Responsive, Resilient, and Respectful.
We’re currently recruiting for a Senior Director, Corporate Counsel to join our Legal team on a 12 month fixed-term contract. In this role, you willprovide legal advice on corporate and company secretarial matters, partnering with the Chief Legal Officer to protect the Group, enable delivery of its strategy and maintain high standards of legal compliance playing a key part in advancing our mission and making a real difference.
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors, the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing development and manufacturing expertise for lentiviral, AAV, adenoviral, MVA and other viral vectors. Building on its viral vector leadership, OXB also supports the development of emerging in vivo therapies through its expertise in vector engineering, manufacturing platforms, and novel envelope technologies. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US.
We want you to feel inspired every day. At OXB, we’re future-focused and growing fast. We succeed together—through passion, commitment, and teamwork.